This week a German team presented data from a database analysis study that found a link between a diabetes drug and a slight dip in the risk of developing Alzheimer's.
Jeffrey Cummings is directing one of the few early-stage studies underway on an Alzheimer's therapy. And now that he's scanned the records of clinicaltrials.gov, he's acutely aware of just how small his chosen field is.
Promising to use its technology to enhance the efficacy and safety of currently approved Alzheimer's drugs, Chase Pharmaceuticals says it has now added $21 million in new venture cash.
Merck may lead the industry in developing a new BACE inhibitor for Alzheimer's, but AstraZeneca feels that it has a shot at blockbuster glory in the field as well. And now the pharma giant wants to rope a partner in to share the potential rewards, as well as the high level of risk involved--if not just take over the whole thing.
Researchers at Rice University in Texas have developed a new kind of drug delivery particle: a "tunable" virus that releases a treatment only in the presence of not one but two different enzymes that show elevated levels at the site of a tumor.
About 7 months after splitting her company into two biotechs, CEO Nancy Stagliano has sold iPierian and its preclinical foray against neurodegenerative diseases--including Alzheimer's--to Bristol-Myers Squibb for $175 million down and up to $550 million in milestones.
Researchers at the University of California, San Francisco, have launched a new online database to help reduce the time and cost of conducting clinical trials for brain ailments.
The team concluded that a protein called REST--particularly active in the brains of fetuses and now emerging as a key gene regulator in older brains--also appears to protect neurons in the elderly.
Researchers at Shanghai Jiao Tong University in China have developed nanoparticles capable of crossing the blood-brain barrier that could potentially help to clear amyloid-β proteins, which are associated with Alzheimer's disease.
Certain biomarkers that can point to the presence of Alzheimer's build and then peak in the body over a period of years and then drop after symptoms appear, researchers have determined.